SLP
Simulations Plus, Inc.
Medical - Healthcare Information Services
Market Cap$320M
5Y Perf.-68.7%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
SLP vs TMO
Revenue, margins, valuation, and 5-year total return — side by side.
TMO
Thermo Fisher Scientific Inc.
Medical - Diagnostics & Research
Market Cap$175.76B
5Y Perf.+35.4%
SLP vs TMO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | SLP | TMO |
|---|---|---|
| Industry | Medical - Healthcare Information Services | Medical - Diagnostics & Research |
| Market Cap | $320M | $175.76B |
| Revenue (TTM) | $79M | $45.20B |
| Net Income (TTM) | $-64M | $6.86B |
| Gross Margin | 59.6% | 39.4% |
| Operating Margin | -89.2% | 17.8% |
| Forward P/E | 17.8x | 19.0x |
| Total Debt | $616K | $40.85B |
| Cash & Equiv. | $31M | $9.86B |
SLP vs TMO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
SLP
TMO
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Simulations Plus, I… (SLP) | 100 | 31.3 | -68.7% |
| Thermo Fisher Scien… (TMO) | 100 | 135.4 | +35.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SLP vs TMO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: TMO leads in 5 of 7 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Simulations Plus, Inc. is the stronger pick specifically for growth and revenue expansion and valuation and capital efficiency. As sector peers, any of these can serve as alternatives in the same allocation.
SLP
Simulations Plus, Inc.
The Growth Play
SLP is the clearest fit if your priority is growth exposure and sleep-well-at-night.
- Rev growth 13.1%, EPS growth -7.6%, 3Y rev CAGR 13.7%
- Lower volatility, beta 1.25, Low D/E 0.5%, current ratio 7.67x
- 13.1% revenue growth vs TMO's 3.9%
Best for: growth exposure and sleep-well-at-night
TMO
Thermo Fisher Scientific Inc.
The Income Pick
TMO carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 8 yrs, beta 1.10, yield 0.4%
- 229.1% 10Y total return vs SLP's 113.8%
- Beta 1.10, yield 0.4%, current ratio 1.89x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | SLP | 13.1% revenue growth vs TMO's 3.9% |
| Value | SLP | Lower P/E (17.8x vs 19.0x) |
| Quality / Margins | TMO | 15.2% margin vs SLP's -81.7% |
| Stability / Safety | TMO | Beta 1.10 vs SLP's 1.25 |
| Dividends | TMO | 0.4% yield; 8-year raise streak; the other pay no meaningful dividend |
| Momentum (1Y) | TMO | +16.6% vs SLP's -45.3% |
| Efficiency (ROA) | TMO | 6.4% ROA vs SLP's -46.6%, ROIC 7.5% vs -39.6% |
SLP vs TMO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
SLP vs TMO — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLTMOLAGGINGSLP
SLPSimulations Plus, Inc.
1leads
TMOThermo Fisher Scienti…
4leads
6 Total Categories
CATEGORYLEADERvs SLPMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
Tied
—
Valuation MetricsMultiples, price ratios, and targets
SLP4/5
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
TMO4/7
Total Returns1Y, 3Y, 5Y total returns with dividends
TMO5/6
Risk & VolatilityBeta, volatility, and downside exposure
TMO2/2
Analyst OutlookRatings, price targets, and dividends
TMO1/1
Income & Cash Flow (Last 12 Months)
Evenly matched — SLP and TMO each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
TMO is the larger business by revenue, generating $45.2B annually — 574.5x SLP's $79M. TMO is the more profitable business, keeping 15.2% of every revenue dollar as net income compared to SLP's -81.7%. On growth, TMO holds the edge at +6.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | SLPSimulations Plus,… | TMOThermo Fisher Sci… |
|---|---|---|
| RevenueTrailing 12 months | $79M | $45.2B |
| EBITDAEarnings before interest/tax | -$63M | $10.5B |
| Net IncomeAfter-tax profit | -$64M | $6.9B |
| Free Cash FlowCash after capex | $23M | $6.7B |
| Gross MarginGross profit ÷ Revenue | +59.6% | +39.4% |
| Operating MarginEBIT ÷ Revenue | -89.2% | +17.8% |
| Net MarginNet income ÷ Revenue | -81.7% | +15.2% |
| FCF MarginFCF ÷ Revenue | +29.2% | +14.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | -2.7% | +6.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +2.3% | +11.3% |
Evenly matched — SLP and TMO each lead in 3 of 6 comparable metrics.
Valuation Metrics
SLP leads this category, winning 4 of 5 comparable metrics.
Valuation Metrics
| Metric | SLPSimulations Plus,… | TMOThermo Fisher Sci… |
|---|---|---|
| Market CapShares × price | $320M | $175.8B |
| Enterprise ValueMkt cap + debt − cash | $290M | $206.8B |
| Trailing P/EPrice ÷ TTM EPS | -4.93x | 26.66x |
| Forward P/EPrice ÷ next-FY EPS est. | 17.81x | 19.04x |
| PEG RatioP/E ÷ EPS growth rate | — | 12.62x |
| EV / EBITDAEnterprise value multiple | — | 18.99x |
| Price / SalesMarket cap ÷ Revenue | 4.04x | 3.94x |
| Price / BookPrice ÷ Book value/share | 2.56x | 3.33x |
| Price / FCFMarket cap ÷ FCF | 18.37x | 27.93x |
SLP leads this category, winning 4 of 5 comparable metrics.
Profitability & Efficiency
TMO leads this category, winning 4 of 7 comparable metrics.
Profitability & Efficiency
TMO delivers a 13.2% return on equity — every $100 of shareholder capital generates $13 in annual profit, vs $-51 for SLP. SLP carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to TMO's 0.76x.
| Metric | SLPSimulations Plus,… | TMOThermo Fisher Sci… |
|---|---|---|
| ROE (TTM)Return on equity | -50.5% | +13.2% |
| ROA (TTM)Return on assets | -46.6% | +6.4% |
| ROICReturn on invested capital | -39.6% | +7.5% |
| ROCEReturn on capital employed | -44.1% | +9.1% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 6 |
| Debt / EquityFinancial leverage | 0.00x | 0.76x |
| Net DebtTotal debt minus cash | -$30M | $31.0B |
| Cash & Equiv.Liquid assets | $31M | $9.9B |
| Total DebtShort + long-term debt | $616,000 | $40.9B |
| Interest CoverageEBIT ÷ Interest expense | — | 5.89x |
TMO leads this category, winning 4 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
TMO leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in TMO five years ago would be worth $10,211 today (with dividends reinvested), compared to $2,951 for SLP. Over the past 12 months, TMO leads with a +16.6% total return vs SLP's -45.3%. The 3-year compound annual growth rate (CAGR) favors TMO at -4.2% vs SLP's -26.3% — a key indicator of consistent wealth creation.
| Metric | SLPSimulations Plus,… | TMOThermo Fisher Sci… |
|---|---|---|
| YTD ReturnYear-to-date | -12.3% | -20.1% |
| 1-Year ReturnPast 12 months | -45.3% | +16.6% |
| 3-Year ReturnCumulative with dividends | -60.0% | -11.9% |
| 5-Year ReturnCumulative with dividends | -70.5% | +2.1% |
| 10-Year ReturnCumulative with dividends | +113.8% | +229.1% |
| CAGR (3Y)Annualised 3-year return | -26.3% | -4.2% |
TMO leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
TMO leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
TMO is the less volatile stock with a 1.10 beta — it tends to amplify market swings less than SLP's 1.25 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TMO currently trades 73.4% from its 52-week high vs SLP's 46.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SLPSimulations Plus,… | TMOThermo Fisher Sci… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.25x | 1.10x |
| 52-Week HighHighest price in past year | $34.01 | $643.99 |
| 52-Week LowLowest price in past year | $11.09 | $385.46 |
| % of 52W HighCurrent price vs 52-week peak | +46.7% | +73.4% |
| RSI (14)Momentum oscillator 0–100 | 66.8 | 39.8 |
| Avg Volume (50D)Average daily shares traded | 312K | 1.9M |
TMO leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
TMO leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Wall Street rates SLP as "Buy" and TMO as "Buy". Consensus price targets imply 252.6% upside for SLP (target: $56) vs 38.4% for TMO (target: $655). TMO is the only dividend payer here at 0.36% yield — a key consideration for income-focused portfolios.
| Metric | SLPSimulations Plus,… | TMOThermo Fisher Sci… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $56.00 | $654.67 |
| # AnalystsCovering analysts | 8 | 42 |
| Dividend YieldAnnual dividend ÷ price | — | +0.4% |
| Dividend StreakConsecutive years of raises | 4 | 8 |
| Dividend / ShareAnnual DPS | — | $1.69 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.7% |
TMO leads this category, winning 1 of 1 comparable metric.
Key Takeaway
TMO leads in 4 of 6 categories (Profitability & Efficiency, Total Returns). SLP leads in 1 (Valuation Metrics). 1 tied.
Best OverallThermo Fisher Scientific In… (TMO)Leads 4 of 6 categories
Loading custom metrics...
SLP vs TMO: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is SLP or TMO a better buy right now?
For growth investors, Simulations Plus, Inc.
(SLP) is the stronger pick with 13. 1% revenue growth year-over-year, versus 3. 9% for Thermo Fisher Scientific Inc. (TMO). Thermo Fisher Scientific Inc. (TMO) offers the better valuation at 26. 7x trailing P/E (19. 0x forward), making it the more compelling value choice. Analysts rate Simulations Plus, Inc. (SLP) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — SLP or TMO?
On forward P/E, Simulations Plus, Inc.
is actually cheaper at 17. 8x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — SLP or TMO?
Over the past 5 years, Thermo Fisher Scientific Inc.
(TMO) delivered a total return of +2. 1%, compared to -70. 5% for Simulations Plus, Inc. (SLP). Over 10 years, the gap is even starker: TMO returned +229. 1% versus SLP's +113. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — SLP or TMO?
By beta (market sensitivity over 5 years), Thermo Fisher Scientific Inc.
(TMO) is the lower-risk stock at 1. 10β versus Simulations Plus, Inc. 's 1. 25β — meaning SLP is approximately 14% more volatile than TMO relative to the S&P 500. On balance sheet safety, Simulations Plus, Inc. (SLP) carries a lower debt/equity ratio of 0% versus 76% for Thermo Fisher Scientific Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — SLP or TMO?
By revenue growth (latest reported year), Simulations Plus, Inc.
(SLP) is pulling ahead at 13. 1% versus 3. 9% for Thermo Fisher Scientific Inc. (TMO). On earnings-per-share growth, the picture is similar: Thermo Fisher Scientific Inc. grew EPS 7. 3% year-over-year, compared to -757. 1% for Simulations Plus, Inc.. Over a 3-year CAGR, SLP leads at 13. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — SLP or TMO?
Thermo Fisher Scientific Inc.
(TMO) is the more profitable company, earning 15. 1% net margin versus -81. 7% for Simulations Plus, Inc. — meaning it keeps 15. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TMO leads at 18. 2% versus -89. 3% for SLP. At the gross margin level — before operating expenses — SLP leads at 58. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is SLP or TMO more undervalued right now?
On forward earnings alone, Simulations Plus, Inc.
(SLP) trades at 17. 8x forward P/E versus 19. 0x for Thermo Fisher Scientific Inc. — 1. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SLP: 252. 6% to $56. 00.
08Which pays a better dividend — SLP or TMO?
In this comparison, TMO (0.
4% yield) pays a dividend. SLP does not pay a meaningful dividend and should not be held primarily for income.
09Is SLP or TMO better for a retirement portfolio?
For long-horizon retirement investors, Thermo Fisher Scientific Inc.
(TMO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 10), +229. 1% 10Y return). Both have compounded well over 10 years (TMO: +229. 1%, SLP: +113. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between SLP and TMO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(SLP: -2.7% · TMO: 6.2%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.